N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00692718

Enrollment

160

Registered

2008-06-06

Start date

2008-07-31

Completion date

Unknown

Last updated

2008-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Heart Failure, Acute Myocardial Infarction

Brief summary

Our study is to investigate the effect of N-3 Fatty Acids for the prevention of atrial fibrillation in patients with acute heart failure or acute myocardial infarction

Interventions

DRUGEpadel, Eicosapentaenoic acid

Epadel 900mg, 2 times a day, during hospitalization

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* sinus rhythm patients with acute heart failure or acute myocardial infarction

Exclusion criteria

* pregnancy,allergy to epadel

Design outcomes

Primary

Measure	Time frame
detection of atrial fibrillation on ECG monitoring	anytime during hospitalization

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026